DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research. Learn more about our innovative pipeline today! @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook
Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
- June 2024:- AstraZeneca- A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors. This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
- June 2024:- Genentech Inc.- A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma. The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
- DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
- The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
- Promising Pancreatic Ductal Adenocarcinoma Therapies such as Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.
Stay informed about the cutting-edge advancements in Pancreatic Ductal Adenocarcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment
Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile
- Onvansertib: Cardiff Oncology
Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.
- Nadunolimab: Cantargia
Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy
- Zimberelimab: Arcus Biosciences
Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.
Learn more about Pancreatic Ductal Adenocarcinoma Drugs opportunities in our groundbreaking A Pancreatic Ductal Adenocarcinoma Research and development projects @ Pancreatic Ductal Adenocarcinoma Unmet Needs
Pancreatic Ductal Adenocarcinoma Companies
Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover the latest advancements in Pancreatic Ductal Adenocarcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology disease @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report
- Coverage- Global
- Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others.
- Pancreatic Ductal Adenocarcinoma Therapies- Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin, mFOLFIRINOX, and others.
- Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Pancreatic Ductal Adenocarcinoma Pipeline on our website @ Pancreatic Ductal Adenocarcinoma Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Pancreatic Ductal Adenocarcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- NIS 793: XOMA
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CEND 1: Cend Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- DCC-3116: Deciphera Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RMC-6236: REVOLUTION Medicines
- Drug profiles in the detailed report…..
- Inactive Products
- Pancreatic Ductal Adenocarcinoma Key Companies
- Pancreatic Ductal Adenocarcinoma Key Products
- Pancreatic Ductal Adenocarcinoma- Unmet Needs
- Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
- Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
- Pancreatic Ductal Adenocarcinoma Analyst Views
- Pancreatic Ductal Adenocarcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/